Canine Antivascular Drugs Against Cancer
The CADAC’s objective is to test ET-D5, a First-in-Class small molecule with an original anti-vascular and cytostatic mechanism of action, in a clinical trial in dogs with specific and spontaneous cancers. ET-D5 is a new chemical entity (NCE) and our objective is to bring it onto the canine oncology market as soon as possible. CADAC represents the first-in-dog clinical trial, and is susceptible to bring ET-D5 to the market within 1.5 years after its conclusion.
1 647 920.00€
In vitro Testing, Trials
Other therapeutic (including defibrillators)